NanoViricides, Inc. (NYSE American: NNVC) announced the filing of its quarterly report for the period ended March 31, 2026, detailing continued progress on its broad-spectrum antiviral candidate NV-387. The company has secured regulatory approval to initiate a Phase II clinical trial for MPox in the Democratic Republic of Congo, a critical step in addressing the ongoing outbreak. Additionally, the U.S. Food and Drug Administration granted orphan drug designation for NV-387 for the treatment of measles subsequent to the quarter, with further applications targeting MPox and smallpox under review.
The company's orphan-first regulatory strategy aims to leverage the benefits of orphan drug status, including expedited development and marketing incentives, to accelerate the path to approval for NV-387. This approach is particularly significant given the urgent need for effective treatments against emerging and re-emerging viral threats. NV-387 is designed as a broad-spectrum antiviral, with potential applications against respiratory syncytial virus (RSV), COVID-19, Long COVID, influenza, MPox, smallpox, and measles. The drug's nanoviricide platform utilizes special purpose nanomaterials to target viruses directly, offering a novel mechanism of action that could overcome limitations of existing therapies.
Beyond MPox and measles, NanoViricides is advancing NV-387 for respiratory viral infections. The company previously reported positive preclinical data for NV-CoV-2 (API NV-387) against COVID-19 and is exploring its use in combination with remdesivir (NV-CoV-2-R). The company believes that encapsulating remdesivir within its polymeric micelles could enhance efficacy and safety, potentially leading to an approvable drug candidate. NanoViricides also maintains a pipeline targeting herpes viruses, influenza, HIV, hepatitis C, rabies, dengue, and Ebola, among others.
For more details on the quarterly report and NV-387 development, visit the company's newsroom at https://ibn.fm/NNVC. The full press release is available at https://ibn.fm/osO0q.
NanoViricides' platform technology is licensed from TheraCour Pharma, Inc., and the company holds exclusive licenses for several antiviral indications. However, the company cautions that drug development is inherently risky and capital-intensive, and there is no assurance that any candidate will successfully complete clinical trials or receive regulatory approval. Investors are encouraged to review the company's filings for a comprehensive discussion of risk factors.
